Stockreport

Carmot Therapeutics Begins U.S. IPO Rollout [Seeking Alpha]

Lyell Immunopharma, Inc.  (LYEL) 
PDF The firm's lead candidate, CT-388, has shown statistically significant weight loss in Phase 1/2 trials, at least from initial data. The global market for obesity trea [Read more]